117 related articles for article (PubMed ID: 31241542)
1. Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years.
Bwakura Dangarembizi M; Samson P; Capparelli EV; Moore CB; Jean-Philippe P; Spector SA; Chakhtoura N; Benns A; Zimmer B; Purdue L; Jackson C; Wallis C; Libous JL; Chadwick EG;
J Acquir Immune Defic Syndr; 2019 Aug; 81(4):473-480. PubMed ID: 31241542
[TBL] [Abstract][Full Text] [Related]
2. CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection.
Bolton Moore C; Capparelli EV; Samson P; Bwakura-Dangarembizi M; Jean-Philippe P; Worrell C; Heckman B; Purdue L; Spector SA; Benns A; Borkowsky W; Loftis A; Hawkins E; Wallis C; Chadwick EG;
AIDS; 2017 May; 31(8):1129-1136. PubMed ID: 28323755
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing.
Alghamdi WA; Antwi S; Enimil A; Yang H; Dompreh A; Wiesner L; Langaee T; Peloquin CA; Kwara A
J Antimicrob Chemother; 2019 Sep; 74(9):2698-2706. PubMed ID: 31243456
[TBL] [Abstract][Full Text] [Related]
4. CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.
Mukonzo JK; Bisaso RK; Ogwal-Okeng J; Gustafsson LL; Owen JS; Aklillu E
Pharmacogenomics; 2016 Apr; 17(6):603-13. PubMed ID: 27045425
[TBL] [Abstract][Full Text] [Related]
5. Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment.
Gengiah TN; Botha JH; Yende-Zuma N; Naidoo K; Abdool Karim SS
Antivir Ther; 2015; 20(3):297-306. PubMed ID: 25318122
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.
Habtewold A; Aklillu E; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Owen JS; Burhenne J
J Clin Pharmacol; 2016 Dec; 56(12):1538-1549. PubMed ID: 27125860
[TBL] [Abstract][Full Text] [Related]
7. High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment.
von Braun A; Castelnuovo B; Ledergerber B; Cusato J; Buzibye A; Kambugu A; Fehr J; Calcagno A; Lamorde M; Sekaggya-Wiltshire C
J Antimicrob Chemother; 2019 Jan; 74(1):135-138. PubMed ID: 30239753
[TBL] [Abstract][Full Text] [Related]
8. CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.
Dhoro M; Zvada S; Ngara B; Nhachi C; Kadzirange G; Chonzi P; Masimirembwa C
BMC Pharmacol Toxicol; 2015 Mar; 16():4. PubMed ID: 25889207
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review.
Atwine D; Bonnet M; Taburet AM
Br J Clin Pharmacol; 2018 Aug; 84(8):1641-1658. PubMed ID: 29624706
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.
Luo M; Chapel S; Sevinsky H; Savant I; Cirincione B; Bertz R; Roy A
Antimicrob Agents Chemother; 2016 Jun; 60(6):3676-86. PubMed ID: 27067333
[TBL] [Abstract][Full Text] [Related]
12. Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old.
Enimil A; Antwi S; Yang H; Dompreh A; Alghamdi WA; Gillani FS; Orstin A; Bosomtwe D; Opoku T; Norman J; Wiesner L; Langaee T; Peloquin CA; Court MH; Greenblatt DJ; Kwara A
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332062
[TBL] [Abstract][Full Text] [Related]
13. Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.
Soeria-Atmadja S; Österberg E; Gustafsson LL; Dahl ML; Eriksen J; Rubin J; Navér L
PLoS One; 2017; 12(9):e0181316. PubMed ID: 28886044
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age.
Nikanjam M; Tran L; Chadwick EG; Bwakura-Dangarembizi M; Bolton Moore C; Samson P; Spector SA; Chakhtoura N; Jean-Philippe P; Frenkel L; Zimmer B; Benns A; Libous J; Capparelli EV
AIDS; 2022 Mar; 36(4):525-532. PubMed ID: 34873089
[TBL] [Abstract][Full Text] [Related]
15. Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype.
Kitabi EN; Minzi OMS; Mugusi S; Sasi P; Janabi M; Mugusi F; Bertilsson L; Burhenne J; Aklillu E
Sci Rep; 2018 Nov; 8(1):16316. PubMed ID: 30397233
[TBL] [Abstract][Full Text] [Related]
16. Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old.
Kwara A; Yang H; Antwi S; Enimil A; Gillani FS; Dompreh A; Ortsin A; Opoku T; Bosomtwe D; Sarfo A; Wiesner L; Norman J; Alghamdi WA; Langaee T; Peloquin CA; Court MH; Greenblatt DJ
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397066
[TBL] [Abstract][Full Text] [Related]
17. Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.
Habtewold A; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Burhenne J; Aklillu E
Pharmacogenomics; 2015; 16(10):1047-64. PubMed ID: 25831219
[TBL] [Abstract][Full Text] [Related]
18. Efavirenz Capsule Sprinkle and Liquid Formulations With Didanosine and Emtricitabine in HIV-1-infected Infants and Children 3 Months to 6 Years of Age: Study AI266-922.
Pavia-Ruz N; Rossouw M; Sáez-Llorens X; Bunupuradah T; Taylor M; Yang R; Sevinsky H; Krystal M; Lataillade M; Seekins D; Biguenet S
Pediatr Infect Dis J; 2015 Dec; 34(12):1355-60. PubMed ID: 26379163
[TBL] [Abstract][Full Text] [Related]
19. The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients.
Bienvenu E; Swart M; Dandara C; Ashton M
Antiviral Res; 2014 Feb; 102():44-53. PubMed ID: 24316028
[TBL] [Abstract][Full Text] [Related]
20. Genetic and non-genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus-1-infected children in Ethiopia.
Chala A; Kitabi EN; Ahmed JH; Tadesse BT; Chaka TE; Makonnen E; Aklillu E
CPT Pharmacometrics Syst Pharmacol; 2023 Jun; 12(6):783-794. PubMed ID: 36840416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
